Autonomix Medical Receives Nasdaq Delisting Warning for Sub-$1.00 Bid Price
AMIX is trading near its 52-week low of $0.461 (0.6% above the low).
Summary
Autonomix Medical received a deficiency letter from Nasdaq for failing to maintain the minimum $1.00 bid price, initiating a 180-day compliance period to avoid potential delisting.
Key Events · Corporate Governance and Compliance · AMIX
-
Nasdaq Deficiency Notice Received
On January 14, 2026, Autonomix Medical, Inc. received a letter from Nasdaq notifying it of non-compliance with the minimum $1.00 bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
-
180-Day Compliance Period
The company has an initial period of 180 calendar days, until July 13, 2026, to regain compliance. To do so, its common stock must close at $1.00 or more for a minimum of 10 consecutive business days.
-
Potential Delisting Risk
Failure to regain compliance could result in the delisting of the company's common stock from the Nasdaq Capital Market, potentially moving to an over-the-counter market.
-
Consideration of Reverse Stock Split
The company intends to monitor its stock price and may consider options to regain compliance, including a reverse stock split, if necessary.
Analysis · AMIX · Industrial Applications And Services
Autonomix Medical, Inc. received a deficiency letter from Nasdaq due to its common stock trading below the minimum $1.00 bid price for 30 consecutive business days. This is a critical event as failure to regain compliance within the 180-day period could lead to delisting from the Nasdaq Capital Market, significantly impacting the company's liquidity and investor confidence. The company is currently trading near its 52-week low, making the challenge to meet the $1.00 threshold more difficult. A reverse stock split is a common, though often dilutive, measure companies take in such situations to boost share price.
At the time of this filing, AMIX was trading at $0.46 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $0.46 to $3.33. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.